Is Nexentis Technologies Inc. (NXTS) a Buy, Sell, or Hold?
NASDAQ : NXTS
Nexentis Technologies Inc.
$1.8 USD
-$0.11 (-5.76%)
- Volume
- 18.92K
- Average Volume
- 1.31M
- Market Capitalization
- $101.87K
- P/E Ratio
- -0.26
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $75.71
- Year Low
- $1.76
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.73
Company Overview
NASDAQ
David Palach
Agricultural Inputs
Basic Materials
NXTS
7
IL
USD
Liquidity Metrics
0.03
4.73
4.73
2.47
0.00
Sales & Valuation
-$
-44.19
144.53
-0.66
-0.01
Profitability
-$25.02
-$4.05M
15562.12%
14853.03%
-94.06%
-62.63%
P/E Metrics
-0.26
0.00
0.00
Analyst Price Target & Rating
3/5
0 Analysts
%
Financial Health Scores
-5.53
3/9
$6.48M
$16.4M
$3.54M
-$10.74M
Key Metrics (TTM)
-$1.01M
15.34
0.11
4.73
-94.06%
-45.33%
-0.55%
-151.49%
-795 days
Company Executives
| Name | Title |
|---|---|
| Galit Kenigsberg | Head of Sustainability Operations of scientific advisory board |
| Lital Barda | CFO, Financial Controller, Treasurer & Secretary |
| David Palach | Chief Executive Officer |
Poll Results
No votes yet today — be the first to share your view!
About Nexentis Technologies Inc. (NASDAQ:NXTS) Stock
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel. ...
2026-07-07 08:25:00
MitoCareX Bio completes comprehensive SLC transport protein analysis to support discovery of small molecules for hard-to-treat cancers and inflammatory metabolic diseases and enters an AI-driven small-molecule discovery initiative with Boltz
2026-06-29 08:20:00
Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced the signing of an Addendum to the Loan and Partnership Agreement, together with Solterra Renewable Energy Ltd. (“Solterra”) and the other lenders, for its Melz solar PV project in Germany.
2026-06-22 08:22:00
MITOLINE ® -Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets
2026-06-17 07:32:00
Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), today reported that it has completed a broad structural analysis of human SLC (Solute Carrier) transport proteins as part of its ongoing efforts to expand and refine its small-molecule discovery capabilities.
2026-05-18 09:30:00
Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.
2026-05-13 07:07:00
MITOLINE-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development Neve Yarak, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd.
2026-05-13 07:07:00
MITOLINE ® -Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development
2026-05-05 07:32:00
Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), ("Nexentis" or the "Company"), a drug discovery company that is also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd.
Frequently Asked Questions
-
What is the current Nexentis Technologies Inc. (NXTS) stock price?
-
Nexentis Technologies Inc.(NASDAQ:NXTS) stock price is $1.8 in the last trading session. During the trading session, NXTS stock reached the peak price of $75.705 while $1.76 was the lowest point it dropped to. The percentage change in NXTS stock occurred in the recent session was --5.76% while the dollar amount for the price change in NXTS stock was -$0.11.
-
NXTS's industry and sector of operation?
-
The NASDAQ listed NXTS is part of Agricultural Inputs industry that operates in the broader Basic Materials sector.
-
Who are the executives of NXTS?
-
Galit Kenigsberg | Head of Sustainability Operations of scientific advisory board
Lital Barda | CFO, Financial Controller, Treasurer & Secretary
David Palach | Chief Executive Officer
|
| -
How many employees does NXTS have?
-
Number of NXTS employees currently stands at 7. NXTS operates from Pinhas Sapir St. 3, Ness Ziona, TA 7403626, IL.
-
Link for NXTS official website?
-
Official Website of NXTS is: https://www.nexentistech.com
-
How do I contact NXTS?
-
NXTS could be contacted at phone #1 561 819 1400 and can also be accessed through its website. NXTS operates from Pinhas Sapir St. 3, Ness Ziona, TA 7403626, IL.
-
How many shares of NXTS are traded daily?
-
The average number of NXTS shares traded daily for last 3 months was 1.31M.
-
What is the market cap of NXTS currently?
-
The market value of NXTS currently stands at $101.87K with its latest stock price at $1.8